# Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

> **NCT00835419** · PHASE2 · COMPLETED · sponsor: **Piramal Enterprises Limited** · enrollment: 12 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** P276-00

## Key facts

- **NCT ID:** NCT00835419
- **Lead sponsor:** Piramal Enterprises Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-04
- **Final completion:** 2012-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00835419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00835419, "Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00835419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*